Australia markets closed

Histogen Inc. (HSTO)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
0.1764-0.0019 (-1.07%)
At close: 04:00PM EDT
0.1771 +0.00 (+0.40%)
After hours: 07:42PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close0.1783
Open0.1848
Bid0.1764 x 900
Ask0.1769 x 1300
Day's range0.1714 - 0.1848
52-week range0.1500 - 1.2300
Volume708,718
Avg. volume3,104,736
Market cap8.866M
Beta (5Y monthly)N/A
PE ratio (TTM)N/A
EPS (TTM)-0.2640
Earnings date09 Aug 2022 - 15 Aug 2022
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est2.25
  • GlobeNewswire

    Histogen to Present at the H.C. Wainwright Global Investment Conference

    SAN DIEGO, May 17, 2022 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company focused on developing both restorative therapeutics and pan-caspase and caspase selective inhibitors focused on treatments for infectious and inflammatory diseases, today announced that Steven J. Mento, Ph.D., Histogen’s Executive Chairman and Interim President and Chief Executive Officer, will present at the H.C. Wainwright Global Investment Conference. On-Demand Presentation DetailsD

  • GlobeNewswire

    Histogen Reports First Quarter 2022 Financial Results and Provides Business Update

    Received $3.75 Million Payment from Allergan Phase 1/2 Study of HST 003 for Cartilage Regeneration in the Knee Ongoing with Top-Line Data Anticipated in the First Half of 2023 SAN DIEGO, May 12, 2022 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company focused on developing both restorative therapeutics and pan-caspase and caspase selective inhibitors focused on treatments for infectious and inflammatory diseases, today reported financial results for the first

  • GlobeNewswire

    Histogen to Report First Quarter 2022 Financial Results and Provide Business Update

    SAN DIEGO, April 28, 2022 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company focused on developing both restorative therapeutics and pan-caspase and caspase selective inhibitors focused on treatments for infectious and inflammatory diseases, today announced that Histogen’s financial results for the first quarter ended March 31, 2022 will be released after the close of market on Thursday, May 12, 2022. About Histogen Inc. Histogen Inc. is a clinical-stage ther